NEW YORK and BOSTON; Oct. 31, 2024 – Accenture has invested, through Accenture Ventures, in 1910 Genetics (or “1910”), a biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation.

AI is playing a key role in drug discovery and vaccine development. Read More.

Generative AI is transforming the life sciences industry, enhancing drug discovery and improving patient care. Learn more.

Accenture helped Biogen with quantum computing to accelerate its pharmaceutical R&D & drug discovery process for improved patient outcomes. Learn more.

Accenture announced it has made a strategic investment, through Accenture Ventures, in QuantHealth, an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients.

Accenture partnered with Discovery Networks International to create a unified global digital platform for its digital content. Read more.

Using synthetic data to improve clinical trials and ultimately make drug development faster and cheaper. Read more.

Accenture used AI to help Lundbeck uncover relationships between genes and diseases for drug development to treat headaches and migraines. Read more.

Accenture research solutions helps bring new efficiency and insight to scientific discovery. Learn about the need to transform lab and scientific data management.

Accenture's cloud-based platform connects scientific research companies with software service providers to solve patient solutions in a faster way. Learn more.